The biotechnology sector is a complex and speculative investment arena therefore highly specialized knowledge is required to assess the scientific basis of this exciting technology.

The biotechnology sector is an exciting, yet complex and speculative investment arena. Assessing the scientific basis of a new technology requires highly specialized knowledge. Evaluating the soundness of a drug's clinical trial results demands a strong understanding of trial design and statistical analysis. To invest in biotech companies, you must look beyond short-term successes and setbacks. That is one of the reasons we have developed IB Pro; because in the long run, good technology wins the biotech game.

Research and Markets have announced the addition of the "InvestBio PRO -- Biotechnology Investing Strategies and Research" subscription/report to their offering.

InvestBio PRO is the leading source of scientific, business and investment analysis in the biotechnology sector. InvestBio PRO members are continually updated with unbiased research, news, and investment ideas on which biotechnology stocks to own, and when to buy and sell. Our Scientific Advisory Board, an experienced team of industry leaders led by Ron Garren, M.D., our Chief Biotechnology Strategist, prepare the unbiased market and company insights. InvestBio PRO will help you become a savvy biotech investor and make well-informed and intelligent decisions necessary for financial success.

The biotechnology sector is an exciting, yet complex and speculative investment arena. Assessing the scientific basis of a new technology requires highly specialized knowledge. Evaluating the soundness of a drug's clinical trial results demands a strong understanding of trial design and statistical analysis. To invest in biotech companies, you must look beyond short-term successes and setbacks. That is one of the reasons we have developed IB Pro; because in the long run, good technology wins the biotech game.

Dr. Garren and other members of our Scientific Advisory Board look at the mid, small and microcap sector of the biotechnology market as one of the most promising areas in which to find immense value. The reasoning for this is simple. A 10x increase is much easier to accomplish for a smaller rather than a larger stock (i.e. moving from $40 million to $400 million versus moving from $4 billion to $40 billion.) On the other hand the risks are greater in the small cap arena so one must choose wisely and spread the bets around.

Dr. Garrens interest lies in evaluating the science, the market and the management of biotechnology companies. Part of his research is directed at ascertaining the likelihood of success in the various clinical trials. Another aspect of his research looks at the type of drug being developed in regards to the medical marketplace, reimbursement issues, and the competitive landscape. He looks at how a company will market a potential drug and how easy it will be to reach the appropriate audience, i.e., will it sell?

Since its inception in June 1999, Dr. Garrens investment strategies have grown our Model Portfolio a remarkable +627.76%, from its initial $100,000 to $727,757. Year-to-date, the model portfolio has already gone up +110.52%. (These figures are as of 08/07/03.)

InvestBio PRO is a newsletter and email alert service, primarily for individual investors, that provides an analysis of the biotechnology sector. This service explains new technology and science in the biotechnology market, evaluates new products and company performances, and assesses their likely impact on the companys future.

InvestBio PRO members receive unbiased research, news, and investing ideas and strategies on which biotechnology stocks to own, and when to buy and sell. Via a website, InvestBio PRO members can access the Archives and track the positions of the stocks in our Model Portfolio. Ron Garren, M.D., our Chief Biotechnology Strategist, and other members of our highly accredited Scientific Advisory Board prepare the unbiased market and company insights so that InvestBio PRO members can make informed investment decisions.

InvestBio is where the intricate and lucrative Wall Street meets the innovative and promising field of Life Sciences. InvestBio PRO members gain awareness to biotechnology companies latest findings and to how these results will affect the biotechnology stock market.

Our highly accredited Scientific Advisory Board is composed of Ron Garren, M.D., Chief Biotechnology Strategist, and other members with longstanding interest, experiences and knowledge in the biotechnology industry. This Board will provide InvestBio PRO members with unbiased reports, news and investing ideas on which biotechnology stocks to own and when to buy and sell.

Biotechnology is a very complex field; assessing the scientific basis of a new technology requires highly specialized knowledge. InvestBio PRO makes complex matters very simple and logical, thus providing you with practical insight so that you can make informed decisions on your biotechnology portfolio.

InvestBio PRO members will gain practical insight to how new drugs will be used and to how they will likely make the stock market move.

InvestBio PRO transcripts use a clean and simple layout; the presented information is easy to read and understand. Over time InvestBio PRO will help you become a savvy biotechnology investor.

Due to the recent ground breaking advances in DNA research, including the mapping of the human genome, biotechnology is positioned to become one of the most promising sectors on Wall Street. Numerous other factors contribute to the vast amount of interest currently placed in biotechnology:

- Groundbreaking medical advances
- Aging of the world's population
- Increased spending for Research & Development
- Sector shift to life sciences
- Expedited drug-approval process
- Built-in demand and new market opportunities
- Continuously increasing speed of microprocessors

The biotechnology sector is often called speculative, and not without reason. As a result, leading industry experts and seasoned financial advisors share the philosophy of using a diversified investment strategy. InvestBio was created to embody this philosophy and to offer biotech opportunities that are structured, diversified, and easy-to-execute.

Key features of the InvestBio subscritption are as follows:

InvestBio Model Portfolio: Access to InvestBio's Model Portfolio. Find out what stocks make up this portfolio, and how they are performing each day and gain access to the trading notes for this portfolio.

InvestBio Alerts: Timely and actionable news, comments, and investment opinions on biotechnology companies, including buy and sell decisions, which are centered on the Investbio Model Portfolio. The Alerts are sent via email to members for quick and knowledgeable investment decisions as the market reacts to the news.

InvestBio Equity Research: Based on updates in the InvestBio Alerts, Equity Research Reports are issued featuring in-depth analysis on selected biotechnology companies. The reports are aimed to provide members with a thorough evaluation of the company fundamentals from a scientific, financial as well as a business standpoint.

InvestBio Stock Watch List: A quarterly update focusing on biotechnology companies that have not yet hit the spotlight of Wall Street. These companies are being closely examined and monitored by our team of biotech experts. These companies could potentially be the next winning stock picks. The Stock Watch List will give our members an opportunity to evaluate the stocks before the events actually unfold.

InvestBio Report: A bi-annual report providing a broad and accurate overview of the biotech-investing sector highlighting the latest developments, e.g. medical breakthroughs and promising research together with updates on companies that make up the InvestBio Model Portfolio. The Report also comments on all of InvestBios products and services, e.g. InvestBios mutual fund.

InvestBio Archives: Access to all online archives including all previous Reports, Alerts and Equity Research Reports, as well as the Model Portfolios trading notes.

InvestBio Ventures: Access to pre-IPO investments (by invitation to accredited investors only.)

For a complete index of this report click on http://www.researchandmarkets.com/reports/35068

REPORT DATA SUMMARY:
InvestBio PRO -- Biotechnology Investing Strategies and Research
Category: Biotechnology
URL: www.researchandmarkets.com/reports/35068

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

- END PRESS RELEASE -